دواعي استعمال Rani 50mg/2ml 5 amp. for i.v/im injection (cancelled)

Ranitidine 50 mg/2 ml solution for IV/IM injection, 5 ampoules (Pharco, Egypt); listed as cancelled in Egyptian directories.

• Some hospitalised patients with pathological hypersecretory conditions or intractable duodenal ulcers, or short-term alternative to oral dosing in patients unable to take oral medication.DailyMed (US National Library of Medicine)

• Headache (sometimes severe); rarely malaise, dizziness, somnolence, insomnia, vertigo, reversible confusion or hallucinations (mainly in severely ill elderly); constipation, diarrhoea, nausea/vomiting, abdominal pain, rare pancreatitis.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Rare: hepatitis (discontinue immediately), arrhythmias (tachycardia, bradycardia, AV block), blood count changes including agranulocytosis and aplastic anaemia, rash/erythema multiforme, hypersensitivity reactions including anaphylaxis and angioedema, acute interstitial nephritis, gynaecomastia/galactorrhoea.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Transient pain at the IM injection site; transient local burning or itching with IV administration.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Hypersensitivity to ranitidine or any ingredient of the product.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Symptomatic response does not preclude gastric malignancy.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Ranitidine is excreted mainly by the kidney: adjust dose in renal impairment; use caution in hepatic dysfunction. Avoid in patients with a history of acute porphyria (may precipitate attacks).نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• False-positive urine protein tests with Multistix may occur; sulfosalicylic acid testing is recommended.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• On 1 April 2020 the US FDA requested withdrawal of all prescription and OTC ranitidine products from the US market because the impurity NDMA (a probable human carcinogen) can increase over time and with storage above room temperature.معلومة عامة عن المادة الفعالة · U.S. Food and Drug Administration (FDA)

• WarfarinAltered prothrombin time reported; monitor closely.DailyMed (US National Library of Medicine)
• ProcainamideHigh ranitidine doses reduce renal excretion of procainamide and N-acetylprocainamide; monitor for toxicity at oral ranitidine doses above 300 mg/day.DailyMed (US National Library of Medicine)
• Ketoconazole, atazanavir, delavirdine, gefitinibAbsorption may be reduced by increased gastric pH (ketoconazole exposure reduced up to 95% at gastric pH >= 6).DailyMed (US National Library of Medicine)
• Triazolam, midazolam, glipizideExposure may increase (oral midazolam up to 65%, triazolam about 30%, glipizide 34%); monitor.DailyMed (US National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; animal studies at up to 160 times the human dose showed no fetal harm. Use in pregnancy only if clearly needed.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Ranitidine is secreted in human milk; use caution in nursing mothers.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• With IV doses >= 100 mg four times daily for 5 days or longer, monitor SGPT (ALT) daily from day 5.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Competitive, reversible inhibitor of histamine at H2 receptors including those on gastric parietal cells (US Zantac injection label).